MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
1.290
-0.060
-4.44%
Closed 13:00 11/25 EST
OPEN
1.360
PREV CLOSE
1.350
HIGH
1.370
LOW
1.260
VOLUME
74.10K
TURNOVER
81.96K
52 WEEK HIGH
2.680
52 WEEK LOW
1.130
MARKET CAP
76.66M
P/E (TTM)
-2.1597
1D
5D
1M
3M
1Y
5Y
Galectin Therapeutics GAAP EPS of -$0.14
Seekingalpha · 11/14 13:52
BRIEF-Galectin Therapeutics Inc Posts Qtrly Loss Per Share of $0.14
Reuters · 11/14 13:08
Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Benzinga · 11/14 12:58
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertensionHepatic Expression of Galectin-3, a Pro-...
GlobeNewswire · 11/01 12:00
Galectin Therapeutics to Present in Upcoming Conferences
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October 17, 2022...
GlobeNewswire · 10/14 12:00
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Galectin Therapeutics (NASDAQ:GALT) <a href="https://s...
Seekingalpha · 10/12 13:05
Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
-Reuters
Benzinga · 10/12 11:54
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA
Galectin Therapeutics Files Investigational New Drug Application for Proposed Head, Neck Cancer Treatment With US FDA
MT Newswires · 10/12 10:37
More
About GALT
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing therapies to improve the lives of patients with fibrotic disease, chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis cirrhosis.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.